Nanobiotix S.A. (EPA:NANO)
France · Delayed Price · Currency is EUR 28.94
-0.14 (-0.48%)
Nov 12, 2026, 9:23 AM CET
Nanobiotix Revenue
Nanobiotix had revenue of 5.55M EUR in the half year ending June 30, 2026, a decrease of -40.24%. This brings the company's total for the last twelve months to 11.51M. In the year 2025, Nanobiotix had annual revenue of 32.59M. That makes Nanobiotix the 36,234th largest company in the world by revenue and 464th in France.
Revenue (ttm)
11.51M
Revenue Growth
+13.27%
P/S Ratio
128.42
Revenue / Employee
117.41K
Employees
98
Market Cap
1.47B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 32.59M | 39.78M | - |
| Dec 31, 2024 | -7.19M | -43.40M | - |
| Dec 31, 2023 | 36.21M | 31.43M | 658.12% |
| Dec 31, 2022 | 4.78M | 2.13M | 80.43% |
| Dec 31, 2021 | 2.65M | 135.00K | 5.37% |
| Dec 31, 2020 | 2.51M | -29.00K | -1.14% |
| Dec 31, 2019 | 2.54M | -938.00K | -26.96% |
| Dec 31, 2018 | 3.48M | -242.53K | -6.52% |
| Dec 31, 2017 | 3.72M | -1.70M | -31.36% |
| Dec 31, 2016 | 5.42M | 1.41M | 35.03% |
| Dec 31, 2015 | 4.02M | 1.24M | 44.91% |
| Dec 31, 2014 | 2.77M | 2.59M | 1,398.23% |
| Dec 31, 2013 | 184.94K | -785.67K | -80.95% |
| Dec 31, 2012 | 970.61K | -389.71K | -28.65% |
| Dec 31, 2011 | 1.36M | 225.46K | 19.87% |
| Dec 31, 2010 | 1.13M | -1.63M | -59.00% |
| Dec 31, 2009 | 2.77M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 142.94M |
| Genfit | 59.49M |
| Cellectis | 55.86M |
| MedinCell | 24.28M |
| Innate Pharma | 9.81M |
| Sensorion | 6.16M |
| Transgene | 5.62M |
| Valerio Therapeutics Société anonyme | 5.55M |
Nanobiotix News
- 17 days ago - Nanobiotix announces updated results from Phase 1 Study 1100 of JNJ-1900 - TheFly
- 18 days ago - NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma - GlobeNewsWire
- 22 days ago - Voting Rights and Shares Capital of the Company - GlobeNewsWire
- 5 weeks ago - Nanobiotix Names Arnd Christ CFO As Rhijn Steps Down - Nasdaq
- 5 weeks ago - Nanobiotix appoints Arnd Christ CFO - TheFly
- 5 weeks ago - NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer - GlobeNewsWire
- 6 weeks ago - Nanobiotix S.A. (NBTX) Earnings Review: Clinical Progress Meets a Cash-Runway Test - AlphaStreet
- 6 weeks ago - NANOBIOTIX Provides First Half 2026 Operational and Financial Update - GlobeNewsWire